Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;123(21):4224-4235.
doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

Kevin Campbell  1 , Julie M Gastier-Foster  2   3   4 , Meegan Mann  2 , Arlene H Naranjo  5 , Collin Van Ryn  5 , Rochelle Bagatell  6 , Katherine K Matthay  7 , Wendy B London  1 , Meredith S Irwin  8 , Hiroyuki Shimada  9 , M Meaghan Granger  10 , Michael D Hogarty  6 , Julie R Park  11 , Steven G DuBois  1
Affiliations

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

Kevin Campbell et al. Cancer. .

Abstract

Background: High-level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma. To the authors' knowledge, less is known regarding these associations in patients with low-level MYCN copy number increases.

Methods: In this retrospective study, the authors classified patients has having tumors with MYCN wild-type tumors, MYCN gain (2-4-fold increase in MYCN signal compared with the reference probe), or MNA (>4-fold increase). Tests of trend were used to investigate ordered associations between MYCN copy number category and features of interest. Log-rank tests and Cox models compared event-free survival and overall survival by subgroup.

Results: Among 4672 patients, 3694 (79.1%) had MYCN wild-type tumors, 133 (2.8%) had MYCN gain, and 845 (18.1%) had MNA. For each clinical/biological feature, the percentage of patients with an unfavorable feature was lowest in the MYCN wild-type category, intermediate in the MYCN gain category, and highest in the MNA category (P<.0001), except for 11q aberration, for which the highest rates were in the MYCN gain category. Patients with MYCN gain had inferior event-free survival and overall survival compared with those with MYCN wild-type. Among patients with high-risk disease, MYCN gain was associated with the lowest response rate after chemotherapy. Patients with non-stage 4 disease (according to the International Neuroblastoma Staging System) and patients with non-high-risk disease with MYCN gain had a significantly increased risk for death, a finding confirmed on multivariable testing.

Conclusions: Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. Cancer 2017;123:4224-4235. © 2017 American Cancer Society.

Keywords: MYCN; amplification; gain; neuroblastoma; ploidy; prognosis; segmental chromosomal aberration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of event-free survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C) and non-stage 4 patients (D). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 1
Figure 1
Kaplan-Meier estimates of event-free survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C) and non-stage 4 patients (D). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 1
Figure 1
Kaplan-Meier estimates of event-free survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C) and non-stage 4 patients (D). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 1
Figure 1
Kaplan-Meier estimates of event-free survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C) and non-stage 4 patients (D). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C), non-stage 4 patients (D), and non-high-risk patients (E). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C), non-stage 4 patients (D), and non-high-risk patients (E). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C), non-stage 4 patients (D), and non-high-risk patients (E). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C), non-stage 4 patients (D), and non-high-risk patients (E). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival for the full cohort (A), high-risk stage 4 patients (B), high-risk patients (C), non-stage 4 patients (D), and non-high-risk patients (E). *Global p-value for effect of MYCN copy number from univariate Cox model adjusted for non-proportional hazards.
See this image and copyright information in PMC

References

    1. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–297. - PMC - PubMed
    1. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23(27):6459–6465. - PubMed
    1. Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010;16(5):1478–1485. - PMC - PubMed
    1. Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014;32(28):3169–3176. - PMC - PubMed
    1. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–1124. - PubMed

MeSH terms

Substances